http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CR-8630-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_132aa5ddba376cda52c2bedb26765245
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-585
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-143
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-14
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-585
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-10
filingDate 2006-09-14-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1e0c7260f9c4b11623dca7cd712c9fc6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5fee613238377a518da0ac217071cf2c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_84abc477f88992602a4ad3ac5697a0e0
publicationDate 2007-06-06-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CR-8630-A
titleOfInvention STABILIZED SUPERSATURED SOLIDS OF LIPOFILIC DRUGS
abstract The present invention relates to a pharmaceutical composition with improved lopophilic drug solution in an aqueous medium. It was found that pharmaceutical compositions comprising a powder of lipophilic compounds such as hormones, and steroids (for example, drospirenone and estradiol valerate) in a molecularly dispersed form together with a vehicle having a specific surface area of at least 250 m2 / g, such as silicon dioxide, for example, silicon dioxide marketed under the name Aeroperl, "has better dissolving properties of the lipophilic drug.
priorityDate 2004-03-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419491762
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID13791
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID24261
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419535674
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID68873
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID457707758

Total number of triples: 37.